146 related articles for article (PubMed ID: 34999587)
1. Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma.
Herrmann T; Mione C; Montoriol PF; Molnar I; Ginzac A; Durando X; Mahammedi H
Oncology; 2022; 100(2):114-123. PubMed ID: 34999587
[TBL] [Abstract][Full Text] [Related]
2. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma.
Aslan V; Kılıç ACK; Sütcüoğlu O; Eraslan E; Bayrak A; Öksüzoğlu B; Tahtacı G; Özdemir N; Üner A; Günel N; Özet A; Yazıcı O
Urol Oncol; 2022 Nov; 40(11):494.e1-494.e10. PubMed ID: 36137881
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
Yekedüz E; Ertürk İ; Tural D; Karadurmuş N; Karakaya S; Hızal M; Arıkan R; Arslan Ç; Taban H; Küçükarda A; Öztaş NŞ; Sever ÖN; Uçar G; Can O; Şendur MA; Demirci U; Kılıçkap S; Çiçin İ; Öksüzoğlu B; Özgüroğlu M; Ürün Y
Future Oncol; 2021 Dec; 17(35):4861-4869. PubMed ID: 34726480
[TBL] [Abstract][Full Text] [Related]
4. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study.
Ueki H; Hara T; Okamura Y; Bando Y; Terakawa T; Furukawa J; Harada K; Nakano Y; Fujisawa M
Investig Clin Urol; 2022 Jul; 63(4):415-424. PubMed ID: 35796138
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
[TBL] [Abstract][Full Text] [Related]
6. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
[TBL] [Abstract][Full Text] [Related]
7. Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.
McManus HD; Zhang D; Schwartz FR; Wu Y; Infield J; Ho E; Armstrong AJ; George DJ; Kruse D; Gupta RT; Harrison MR
Clin Genitourin Cancer; 2023 Dec; 21(6):e429-e437.e2. PubMed ID: 37271698
[TBL] [Abstract][Full Text] [Related]
8. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab.
Yoshimura A; Nagahara A; Ishizuya Y; Yamamoto Y; Hatano K; Kawashima A; Nakai Y; Nakayama M; Nishimura K; Nonomura N; Kato T
Clin Exp Med; 2024 May; 24(1):111. PubMed ID: 38780659
[TBL] [Abstract][Full Text] [Related]
10. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.
Herrmann T; Ginzac A; Molnar I; Bailly S; Durando X; Mahammedi H
Cancer Med; 2021 Oct; 10(19):6705-6713. PubMed ID: 34405573
[TBL] [Abstract][Full Text] [Related]
11. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
[TBL] [Abstract][Full Text] [Related]
12. Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab.
Catalano M; Rebuzzi SE; Maruzzo M; De Giorgi U; Buti S; Galli L; Fornarini G; Zucali PA; Procopio G; Chiellino S; Milella M; Catalano F; Pipitone S; Ricotta R; Sorarù M; Mollica V; Tudini M; Fratino L; Prati V; Caffo O; Atzori F; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Di Napoli M; Malgeri A; Naglieri E; Signori A; Banna GL; Rescigno P; Antonuzzo L; Roviello G
JAMA Netw Open; 2023 Nov; 6(11):e2345185. PubMed ID: 38010650
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma.
Auclin E; Bourillon C; De Maio E; By MA; Seddik S; Fournier L; Auvray M; Dautruche A; Vano YA; Thibault C; Joly F; Brunereau L; Gomez-Roca C; Chevreau C; Elaidi R; Oudard S
Clin Genitourin Cancer; 2017 Jun; 15(3):350-355. PubMed ID: 28216276
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.
Tachibana H; Kondo T; Ishihara H; Takagi T; Tanabe K
Clin Genitourin Cancer; 2019 Aug; 17(4):e772-e778. PubMed ID: 31101580
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
[TBL] [Abstract][Full Text] [Related]
17. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience.
Zhao JJ; Kumarakulasinghe NB; Muthu V; Lee M; Walsh R; Low JL; Choo J; Tan HL; Chong WQ; Ang Y; Chan G; Yong WP; Huang Y; Ngoi N; Wong A
Oncology; 2021; 99(3):192-202. PubMed ID: 33440374
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
Alhalabi O; Hasanov E; Wilson NR; Araujo J; Wang J; Campbell MT; Goswami S; Shah AY; Gao J; Msaouel P; Tannir NM
Int J Cancer; 2021 Jul; 149(2):387-393. PubMed ID: 33739450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
